| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8237391 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 7 Pages |
Abstract
Use of antiangiogenic therapy with radiation and temozolomide in the primary management of high-grade glioma is feasible. Perfusion imaging with relative cerebral blood volume, perfusion-permeability index, and pVEGFR2 expression may be used as a potential predictor of therapeutic response. Toxicities and patterns of relapse need to be monitored closely.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ashwatha M.D., John G. M.D., Ingeborg M.D., Shahzad M.D., Patrick M.D., Erik M.D., Edmond A. M.D., Praveen M.P.H., David M.D., Patricia R.N., Michael L. M.D.,